Mendelian randomization: prospects, potentials, and limitations

George Davey Smith and Shah Ebrahim

In this issue of the International Journal of Epidemiology we reprint a letter to the Lancet by Martijn Katan1 and several commentaries2–7 concerning what has become known as ‘Mendelian randomization’8–12—the use of genotype–disease associations to make inferences about environmentally modifiable causes of disease. Here we will reflect on the prospects, potentials, and limitations of Mendelian randomization.

Where can Mendelian randomization help observational epidemiology?

Mendelian randomization is the term applied to the random assortment of alleles at the time of gamete formation. This results in population distributions of genetic variants that are generally independent of behavioural and environmental factors that typically confound epidemiological associations between putative risk factors and disease. In some circumstances this can provide a study design akin to randomized comparisons.

The principles of Mendelian randomization can serve to limit several potential problems in observational epidemiology (Table 1). The avoidance of confounding is clearly a key advantage, and in view of this, Martin Tobin and colleagues9 have suggested that the approach should be termed ‘Mendelian deconfounding’. However, there are several additional and perhaps equally important ways in which Mendelian randomization can strengthen inferences drawn from observational studies. In the example Katan originally presented—that of the association between low serum cholesterol levels and cancer—the most plausible bias would be introduced by reverse causation. The early stages of cancer could lead to a decrease in circulating cholesterol levels, generating an inverse association between cholesterol levels and cancer morbidity or mortality.1 Early stages of cancer will not, however, change inherited genetic variants that are associated with cholesterol levels. Thus if low cholesterol level were a cause of increased cancer risk then individuals with genetic variants associated with lower cholesterol levels should have a higher cancer risk. If, on the other hand, reverse causation is responsible for the association between cholesterol level and cancer, there should be no association between genetic variants related to cholesterol level and cancer risk. Biological forms of reverse causation may influence many epidemiological associations—for example, those between markers of inflammation and coronary heart disease, where existing atherosclerosis may influence the level of factors such as fibrinogen and C-reactive protein.13 Reverse causation can also occur through exposure assignment—for example, people with early stages of coronary heart disease may take vitamin supplements because they believe these will reduce their risk of cardiovascular events. This will tend to generate a positive association between vitamin intake and disease. A form of reverse causation can also occur through reporting bias, with the presence of disease influencing reporting disposition. In case-control studies people with the disease under investigation may report on their prior exposure history in a different way than do controls—perhaps because the former will think harder about potential reasons that account for why they have developed the disease. In this situation the association between genetic variants related to the exposure and disease outcome will not usually be biased.

In observational studies associations between an exposure and disease will generally be biased if there is selection according to an exposure–disease combination in case-control studies, or according to an exposure–disease risk combination in prospective studies. If, for example, people with an exposure and at low risk of disease for other reasons were differentially excluded from a study the exposure would appear to be positively related to disease outcome, even if there were no such association in the underlying population. This is a form of ‘Berkson’s bias’, well known to epidemiologists.14 A possible example of such associative selection bias relates to the finding in the large American Cancer Society volunteer cohort that high alcohol consumption was associated with a reduced risk of stroke.15 This is somewhat counter-intuitive as the outcome category included haemorrhagic stroke (for which there is no obvious mechanism through which alcohol would reduce risk) and because alcohol is known to increase blood pressure16,17—a major causal factor for stroke.18 Population-based studies have found that alcohol tends to increase stroke risk.19–21 Heavy drinkers who volunteer for a study known to be about the health effects of their lifestyle are likely to be very unrepresentative of all heavy drinkers in the population, in ways that render them to be at low risk of stroke. Moderate and non-drinkers

Table 1 Problems in observational epidemiology where Mendelian randomization may help

<table>
<thead>
<tr>
<th>Problem</th>
<th>Potential solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confounding</td>
<td>Mendelian randomization</td>
</tr>
<tr>
<td>Reverse causation</td>
<td>Dominance of other factors</td>
</tr>
<tr>
<td>Biological</td>
<td>Through Mendelian randomization</td>
</tr>
<tr>
<td>through exposure assignment</td>
<td></td>
</tr>
<tr>
<td>due to reporting bias</td>
<td></td>
</tr>
<tr>
<td>Associative selection bias (Berkson’s bias)</td>
<td></td>
</tr>
<tr>
<td>Attenuation by errors (regression dilution bias)</td>
<td></td>
</tr>
</tbody>
</table>
who volunteer may be more representative of moderate and non-drinkers in the underlying population. Thus the low risk of stroke in the heavy drinkers who volunteer for the study could erroneously make it appear that alcohol reduces the risk of stroke.

Perhaps because it is difficult to directly test for the presence of associative selection it is traditional to claim in the discussion section of epidemiological papers that such selection is unlikely to have occurred. We confess to having used such reasoning ourselves on several occasions, but clearly the use of methods not susceptible to such bias would be preferable. As in the example of heavy drinking and stroke, social processes will often underlie any associative selection bias. In contrast, it is improbable that such social processes will lead to selection of study participants on the basis of associations between a genetic variant and behavioural or other genetic risk factors. Therefore inferences drawn from associations between genetic variants and disease are less likely to be distorted by associative selection bias than is the case in conventional observational epidemiology.

The strength of associations between causal risk factors and disease in observational studies will generally be underestimated due to random measurement imprecision in indexing the exposure. A century ago Charles Spearman demonstrated mathematically how such measurement imprecision would lead to what he termed the ‘attenuation by errors’ of associations. Indeed in the case of homocysteine and coronary heart disease (CHD) the association between MTHFR genotype and CHD, combined with the association between genotype and homocysteine levels, gives an imputed estimate of the homocysteine–CHD association similar to that seen in observational studies after they have been statistically adjusted for attenuation by errors.

### Categories of inference from Mendelian randomization

The principles of Mendelian randomization can be applied in a variety of ways to make inferences about environmentally modifiable determinants of disease. Table 2 provides a provisional categorization of these types of inference. First, a genetic variant could influence exposure through an effect on dispositional propensities. For example, variants that influence the tendency to drink alcohol or milk have been identified, and, as discussed later, these allow investigation of the health effects of alcohol and milk consumption.

### Table 2 Categories of inferences from Mendelian randomization

<table>
<thead>
<tr>
<th>Exposure propensity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intermediate phenotypes</td>
</tr>
<tr>
<td>Single factors</td>
</tr>
<tr>
<td>In situations with correlated intermediate phenotypes</td>
</tr>
<tr>
<td>Modifiers of environmental exposure</td>
</tr>
<tr>
<td>Characterizing ‘difficult to measure’ environmental exposures</td>
</tr>
<tr>
<td>Intergenerational influences</td>
</tr>
<tr>
<td>Indicator of the category of exposure of importance</td>
</tr>
</tbody>
</table>

Second, a genetic variant could influence an intermediate phenotype, such as cholesterol or fibrinogen levels. This provides a method for assessment of the causal nature of observed associations between the intermediate phenotype and disease, and thus whether interventions to modify the intermediate phenotype could be expected to influence disease risk. A further elaboration of this second approach is where intermediate phenotypes are related to each other—as in the case of the strong inverse association between triglyceride levels and HDL cholesterol. In such situations it is statistically difficult—if not impossible—to determine which of the factors has causal priority with respect to CHD risk. Genetic variants associated with differences in one, but not others, of the correlated intermediate phenotypes could be related to disease risk and, in principle, in this way causal factors can be identified. However, in the case of HDL cholesterol, triglyceride, and CHD risk this has so far proved difficult to achieve.

Third, genetic variants that modify the biological response to an environmental exposure—such as genetic variants related to alcohol metabolism or detoxification of organophosphates (as contained in sheep dip, for example) can be taken as indicators of the effects of different levels of exposure (including some exposure versus no exposure), as we have discussed previously.

Fourth, in some circumstances genetic variants can better characterize potentially modifiable exposures that are difficult to measure, either because of technical difficulty (for example, measuring colonic bile salt exposure—see below) or because lifetime exposure is the relevant measure (for example, homocysteine or blood cholesterol levels). Fifth, maternal genotype can be studied as a determinant of intrauterine exposure acting on a developing fetus, in a form of ‘intergenerational Mendelian randomization’. Again we give examples of this below. Finally, genetic variants can be taken in a non-quantitative way to indicate specific or general categories of exposure that may influence disease risk. For example, the identification of a strong link between a frameshift mutation of the NOD2 gene and Crohn’s disease has been taken to strengthen the view that bacterial components of the intestinal flora contribute to Crohn’s disease risk. This is because the mutated gene is involved in sensing and responding to gram-negative bacteria. Perhaps (and in line with data regarding cohort effects in Crohn’s disease incidence) exposure early in life, during colonization by the intestinal flora, is of importance.

We discuss the limitations of Mendelian randomization later in this commentary, but it must be remembered that the inferences outlined above are predicated on establishing robust associations between genetic variants and health outcomes, something which has so far proved difficult in the genetic association study field.

### Mendelian randomization in action

Perhaps a better sense for the potentials of Mendelian randomization comes from considering a few examples of the application...
of these principles. In several of the cases we discuss below we utilize data that were not originally presented in a way that emphasized the inferential strengths of the Mendelian randomization approach. While we categorize these examples according to the framework shown in Table 2, it is clear that some of them provide illustrations of more than one category of inference. These examples also provide practical insights into the limitations of Mendelian randomization, which we have discussed at length elsewhere.12

**Exposure propensity**

**Lactose intolerance and the health effects of drinking milk**

The letter by Katan that we reprint in this issue of the *International Journal of Epidemiology* was an early example of development of the concept of Mendelian randomization. Other—including earlier—examples exist, but the reasoning for the use of genetic variant–disease associations in making inferences about modifiable causes of disease was generally not as clearly formulated as in Katan’s letter. One important early example relates to the longstanding interest in the role of dietary calcium—particularly from milk products—in protection against low bone mineral density, osteoporosis, and fractures. It has been reasoned that people who are lactose intolerant—a state associated with lower intake of the dairy products that provide a high proportion of calcium in the diets of people in North America and Europe—should have an increased risk of these conditions, if low milk (and thus calcium) intake is an important aetiological factor. Several studies have explicitly tested this proposition.38,39 The notion that genetic variation in lactose tolerance may serve as a better index of calcium intake than direct dietary assessment—an example of our category ‘characterizing difficult to measure environmental exposures’—was proposed by Honkanen and colleagues.40

Calcium intake relates only modestly to bone mineral density. One of the main reasons why the verification of this association has been difficult is the lack of accuracy of calcium intake measurements. Self-reported lactose intolerance, as an indicator of long-term low calcium intake, might, therefore, help to detect this slight bone effect better than food frequency enquiry alone.

The association between milk intake and CHD risk has been highly controversial,41 with some studies suggesting that higher consumption may protect people from CHD.42,43 However it has been argued that people with existing heart disease might avoid milk as part of general lifestyle modifications (and this would, of course, generate a non-causal association between milk drinking and lower CHD event rate).44 In some studies there is also evidence of confounding by socio-economic and lifestyle factors, such that people who drink more milk come from more favourable socio-economic backgrounds and exhibit more healthy behavioural profiles.45,46 Adjustment for these factors attenuates the apparent protective effect of milk.43,44 Given the high fat content of milk it might be anticipated that milk would increase coronary risk, but the degree of potential reverse causation and confounding in the observational epidemiological studies leaves the true situation unclear. Segall reported an inverse association between the prevalence of lactose intolerance and CHD mortality in an ecological study, indicating that milk consumption increases risk.45 While this 1980 study could be considered an early example of Mendelian randomization—in that a genetic variant is used as a proxy for a modifiable environmental exposure—ecological studies are prone to confounding by the many factors that differ between countries and could be related to both prevalence of lactose intolerance and CHD risk. Segall proposed that the hypothesis could be tested by direct comparison of the CHD risk in lactose tolerant and lactose intolerant people.45 A case-control study found myocardial infarction risk to be lower in those who were lactose intolerant: odds ratio 0.45 (95% confidence interval 0.19, 1.08; our calculation).46 While full details of the results were not given, the authors concluded that lactose tolerance ‘does not seem to be a risk factor for myocardial infarction by itself but is a precondition for the ability to drink a lot of milk without getting complaints’.46 While these data suggest that milk drinking could increase the risk of CHD it is clear that more powerful studies are required.

Recently a genetic variant underlying lactose intolerance (or at least in tight linkage disequilibrium with such a variant) has been identified.47 Given that some lactose intolerance could be an acquired phenomenon (and therefore potentially related to existing disease and/or confounding factors) and that it takes considerable time and expense to evaluate the lactose intolerance phenotype, the identification of this variant allows for a more reliable and feasible use of lactose intolerance within the Mendelian randomization framework. One situation in which the study of acquired lactose intolerance could confuse interpretation is with respect to inflammatory bowel disease. An increased prevalence of lactose intolerance has been reported in patients with Crohn’s disease,48 but this could be a secondary phenomenon due to the mucosal inflammation consequent on the disease. A recent study demonstrated that this appears to be the case, since there is no difference in prevalence of the genotype related to lactose tolerance between Crohn’s disease patients and controls.49 This is an example of Mendelian randomization being used to study the phenomenon of reverse causation, in this case suggesting that reverse causation was indeed instrumental in generating the observed phenotype–disease association. The genetic variant associated with lactose tolerance has recently been reported to be related both to milk consumption and to the risk of fractures,50 although larger studies are required to confirm this finding.

Lactose intolerance differs markedly between populations, and thus there could be confounding between genotype, population of ancestral origin, and disease outcome. In the USA, for example, people with more recent African roots will have a higher prevalence of lactose intolerance than the European-derived population, and these populations will experience different risks of disease because of environmental or perhaps other genetic factors. Confounded associations between genotype and disease could be generated in this way. This form of confounding is referred to as population stratification, and while there is debate regarding the extent to which this can generate spurious associations,51–53 it remains important to bear this potential problem—common to all population genetic association studies, not just ones within a Mendelian randomization framework—in mind. Furthermore, with the considerable variation in lactose prevalence between populations, the associations between genotype and milk consumption may not be the same in all places. For example, in...
populations where the vast majority of people are lactose tolerant, this may generate cultural pressures such that lactose intolerant people drink at least some milk. This implies that it is always necessary to demonstrate that genetic variants are, indeed, related to the potentially modifiable environmental factor they are taken to proxy for when carrying out studies within the Mendelian randomization framework.

**Intermediate phenotypes**

**Familial hypercholesterolaemia: estimating the cholesterol–CHD association**

Another early example of the use of the principles of Mendelian randomization involves genetic variation in cholesterol levels and CHD risk. Familial hypercholesterolaemia is a dominantly inherited condition in which many rare mutations (over 700 DNA sequence variations\(^{54-56}\)) of the low density lipoprotein receptor gene (about 10 million people affected world-wide, a prevalence of around 0.2%), lead to high circulating cholesterol levels.\(^{57}\) The high risk of premature CHD in people with this condition was readily appreciated, with an early UK report demonstrating that by age 50 half of men and 12% of women had suffered from CHD.\(^{58}\) Compared with the population of England and Wales (mean total cholesterol 6.0 mmol/l), people with familial hypercholesterolaemia (mean total cholesterol 9 mmol/l) suffered a 3.9-fold increased risk of CHD mortality, although very high relative risks among those aged less than 40 years have been observed.\(^{59}\) These observations, regarding genetically determined variation in risk, provided strong evidence that the associations between blood cholesterol and CHD seen in general populations reflected a causal relationship. However, as Ole Færgeman discusses,\(^{60}\) this evidence was not accepted, for a variety of reasons, by many clinical and public health practitioners.

With the advent of effective means of reducing blood cholesterol through statin treatment\(^{61}\) there remains no serious doubt that the cholesterol-CHD relationship is causal. Among people without CHD, reducing total cholesterol levels with statin drugs by around 1–1.5 mmol/l reduces CHD mortality by around 25% over 5 years.\(^{52-64}\) Assuming a linear relationship between blood cholesterol and CHD risk, and given the difference in cholesterol of 3.0 mmol/l between people with familial hypercholesterolaemia and the general population,\(^{59}\) the randomized controlled trial evidence on lowering total cholesterol and reducing CHD mortality would predict a relative risk for CHD of around 2, as opposed to 3.9, for people with familial hypercholesterolaemia. However, the trials also demonstrate that the relative reduction in CHD mortality increases over time from randomization—and thus time with lowered cholesterol—as would be expected if elevated levels of cholesterol operate over decades to influence the development of atherosclerosis. People with familial hypercholesterolaemia will have had high total cholesterol levels throughout their lives and this would be expected to generate a greater risk than that predicted by the results of lowering cholesterol levels for only 5 years. Furthermore, ecological studies relating cholesterol levels to CHD demonstrate that the strength of association increases as the lag period between cholesterol level assessment and CHD mortality increases,\(^{65}\) again suggesting that long-term differences in cholesterol level are the important aetiological factor in CHD.

As discussed above, Mendelian randomization is one method of assessing the effects of long-term differences in exposures on disease risk, free from the diluting problems of both measurement error and of only having short-term assessment of risk factor levels. This approach may provide an indication that cholesterol-lowering efforts should be lifelong, rather than limited to the period for which RCT evidence with respect to CHD outcomes is available.

More recently, mutations in the gene coding for apolipoprotein B (apoB) have been found to produce a syndrome phenotypically indistinguishable from familial hypercholesterolaemia—familial defective ApoB.\(^{66-68}\) In a recent study of the Arg3500Gln mutation of the *APOB* gene, the basic principle behind Mendelian randomization can be demonstrated, in that Arg3500Gln heterozygotes had higher levels of total cholesterol but other CHD risk factors (including triglycerides, fibrinogen, glucose, body mass index and waist-hip ratio) did not differ from non-heterozygotes in the general population.\(^{69}\) The Arg3500Gln heterozygotes had a median 2.6 mmol/l higher blood cholesterol level and a high (but imprecise) odds ratio for CHD of 7.0 (95% CI 2.2, 22) compared with the general population.\(^{59}\) As in the case of familial hypercholesterolaemia this is greater than that predicted by the randomized controlled trial data, but again the differences in cholesterol by genotype will have been life-long, and the elevated CHD risk probably reflects the effects of long-term differences in cholesterol level.

**Indicating the category of exposure causing disease risk**

**Vitamin D, sunlight, tuberculosis, and multiple sclerosis**

In the 18th century, fish oil was a recommended treatment for tuberculosis and in the 1940s reports of use of vitamin D to treat skin tuberculosis (*Lupus vulgaris*) appeared.\(^{70}\) Solaria—rooms to concentrate the sun's rays—were also prevalent as a means of...
have been identified—of which polymorphisms have been most studied in the context of principles of Mendelian randomization may be helpful.

The solarium at Jamnagar, India (above). Lenses and concentrators increase the efficiency of the solarium (below). Photographs: George Davey Smith

treating tuberculosis (see box and Figure 1). More recently, deficiency of vitamin D (25-hydroxycholecalciferol) has been shown to be associated with increased risk of infection with Mycobacterium tuberculosis, with the proposed mechanism implicating 1,25-dihydroxycholecalciferol (the active metabolite of vitamin D) in activating mononuclear phagocytosis of intracellular M. tuberculosis. The epidemiological evidence supporting this association comprises the following observations: an increased risk of tuberculosis among south Asians on migration to Britain’s less sunny climate, which would lead to a reduction in serum vitamin D levels, particularly among vegetarian south Asians living in Britain; equivocal case-control studies comparing serum vitamin D in those with and without tuberculosis; and the annual seasonality of increased incidence of tuberculosis in spring and early summer following the low levels of vitamin D arising during the winter months. Clearly, such observations may be highly confounded by the various known socially and culturally patterned risk factors for tuberculosis. Evidence from a randomized controlled trial of vitamin D supplementation could establish causality and the need for a policy of widespread dietary supplementation of those at high risk. In the absence of such evidence, the principles of Mendelian randomization may be helpful.

Several polymorphisms of the vitamin D receptor (VDR) gene have been identified—of which TaqI, BsmI, ApaI and FokI polymorphisms have been most studied in the context of examining associations with common phenotypes. Rarer mutations of the VDR gene are responsible for the autosomal recessive hereditary vitamin D-resistant rickets, but the functional importance, in terms of VDR expression and function in vitro and vitamin D levels and calcium absorption in vivo, of the common polymorphisms is less clear, with some variants likely to be non-functional (BsmI and ApaI), and with evidence of linkage disequilibrium between TaqI, BsmI, ApaI variants but not FokI. A strong association of the TaqI polymorphism with tuberculosis has been reported among Gambian adults, with the rarer homozygous genotype related odds ratio of tuberculosis being 0.53 (95% CI 0.31, 0.88). This study was interpreted as indicating that this genotype confirmed resistance to tuberculosis, prompting the investigators to suggest that a trial of vitamin D supplementation in tuberculosis was warranted. In a further case-control study among Gujarati adults in London, which examined the association between this same TaqI polymorphism and tuberculosis, the rarer homozygous genotype was less frequent in people with tuberculosis, although the relationship was statistically not robust. A very strong association was found between vitamin D levels and odds of tuberculosis, and apparent interactions between vitamin D deficiency and the non-protective wild type and heterozygous genotypes were found. The FokI combined rarer homozygous and heterozygous genotypes also showed weak evidence of association with tuberculosis risk (odds ratio 1.32, 95% CI 0.72, 2.41) in this study.

Our re-analysis of these data provides a Mendelian randomization assessment of the association between genotype and disease and between vitamin D and disease. Median vitamin D levels were 5 nmol/l higher in controls compared with tuberculosis patients, and the odds ratio for tuberculosis among those with higher levels of vitamin D was 0.17 (95% CI 0.07, 0.39), indicating a strong protective effect. The vitamin D levels between the TaqI genotypes were compared, and a statistically uncertain 3 nmol/l higher level among rarer homozygous and the heterozygous (denoted tt and Tt) genotypes compared with the wild type (denoted TT) genotype was found. Relating the TaqI polymorphism to risk of tuberculosis yields an odds ratio of 0.85 (95% CI 0.47, 1.53) for tt/Tt versus TT, providing weak evidence of a protective effect among those with genotypes conferring a higher vitamin D level. Comparisons of vitamin D levels between the tt and TT genotypes were not reported but might be expected to be larger than 3 nmol/l, and the odds ratio for tuberculosis of tt versus TT genotypes reflects this, with a greater protective effect: odds ratio 0.53 (95% CI 0.15, 1.69), a very similar estimate to that obtained by the Gambian study. Furthermore, the wild type genotype of the FokI polymorphism was associated with a higher vitamin D level of 3.5 nmol/l than the other genotypes, and a similar protective effect on risk of tuberculosis as that observed with the TaqI genotype was found: odds ratio 0.76 (95% CI 0.41, 1.38). These findings are very imprecise, but consistent with the notion that vitamin D deficiency is causally related to increased risk of tuberculosis.

Similar approaches may be applied in examining the hypothesis that vitamin D deficiency is of aetiological importance in multiple sclerosis, where observational epidemiology suggests that sunlight exposure, and hence high vitamin D status, may reduce risk. A report examining the association between the BsmI polymorphism of the VDR gene
and multiple sclerosis has shown an odds ratio of 2.38 (95% CI 1.03, 5.60) comparing the rarer homozygous variant (bb) with the heterozygous and wild type variants.66 giving supportive evidence that vitamin D deficiency may be a causal factor. Vitamin D status and ultraviolet radiation have been implicated in other autoimmune diseases.87,88 and Mendelian randomization may prove helpful in elucidating causality.

Little can currently be concluded from studies relating vitamin D receptor polymorphisms to disease outcomes, partly because whether there is any functional effect of most of the variants that have been studied is uncertain. Furthermore, interpretation is clouded by the fact that a balance may exist between VDR sensitivity and vitamin D levels, both of which may be related to VDR genotype (perhaps in an inter-connected fashion). As in other areas it will be necessary to conduct much bigger and more powerful studies and to better characterize the functional effects of the VDR polymorphisms before any firm conclusions can be reached.

**Aspirin and colon cancer**

In recent years there has been considerable interest in the possibility that aspirin reduces the risk of colon cancer. This interest originated in an unhyphotesized finding in a case-control study exploring a large number of potential risk factors.89 This type of data-derived finding from an observational epidemiological study is particularly unreliable as a clue to aetiology, but several subsequent studies confirmed the finding.90 However, confounding or various potential biases could have generated the association. The consistency and strength of the basic finding is such, however, that randomised controlled trials are planned. Lin and colleagues approached this issue through examining variants in the gene coding for prostaglandin H synthase 2 (PTGS2), an enzyme involved in conversion of arachidonic acid to prostaglandin H2.91 This enzyme is inhibited by aspirin. Through searching for naturally occurring variants, Lin and colleagues detected a single nucleotide polymorphism that produces an amino acid change in the enzyme.91 This variant was seen amongst African-Americans, but not among the other ethnic groups studied. In three small case-control studies Lin et al. found evidence that the variant was associated with a 30–50% reduced risk of colon cancer or colorectal adenomas amongst African-Americans. They hypothesised that naturally occurring PTGS2 variants might mimic long-term aspirin use. Despite a similar association being seen in the three case-control studies, the sample sizes were small, particularly given the variant allele frequency of less than five percent among African-Americans. A larger study is required to confirm these exciting preliminary data. The data do, however, provide supportive evidence that aspirin (and other PTGS2 inhibitors) protect against colon cancer.

**Modifiers of environmental exposures**

**Alcohol intake, aldehyde dehydrogenase genotype, and coronary heart disease**

The possible protective effect of moderate alcohol consumption on CHD risk remains controversial.92–94 Non-drinkers may be at a higher risk of CHD because health problems (perhaps induced by previous alcohol abuse) dissuade them from drinking.95 As well as this form of reverse causation, confounding could play a role, with non-drinkers being more likely to display an adverse profile of socioeconomic or other behavioural risk factors for CHD.96 Alternatively, alcohol may have a direct biological effect that lessens the risk of CHD—for example by increasing the levels of protective high density lipoprotein (HDL) cholesterol.97 It is, however, unlikely that an RCT of alcohol intake, able to test whether there is a protective effect of alcohol on CHD events, will be carried out.

We have previously discussed the investigation of this issue through relating genetic variants associated with alcohol metabolism to CHD risk and HDL cholesterol levels.12 In this earlier case,30 the ADH3 variant was taken to be an indicator of the ‘active’ level of alcohol, given an effect on clearance of alcohol from the system. This association between the ADH3 variant and coronary heart disease is an example of a genetic variant that modifies an environmental exposure, and through this serves as an indicator of the effects of different levels of exposure. However, a more direct way of investigating whether alcohol influences the risk of disease is through the use of genetic variants that influence level of alcohol consumption; an example of ‘exposure propensity’ Mendelian randomization.

Alcohol is oxidized to acetaldehyde, which in turn is oxidized by aldehyde dehydrogenases (ALDHs) to acetate. Half of Japanese people are heterozygotes or homozygotes for a null variant of *ALDH2* and peak blood acetaldehyde concentrations post alcohol challenge are 18 times and 5 times higher among homozgyous null variant and heterozygous individuals compared with homozygous wild type individuals.98 This renders the consumption of alcohol unpleasant through
inducing facial flushing, palpitations, drowsiness, and other symptoms. As Table 3 shows, there are very considerable differences in alcohol consumption according to genotype.\(^{99}\) The principles of Mendelian randomization are seen to apply—two factors that would be expected to be associated with alcohol consumption, age and cigarette smoking, which would confound conventional observational associations between alcohol and disease, are not related to genotype, despite the strong association of genotype with alcohol consumption. It would be expected that ALDH2 genotype influences diseases known to be related to alcohol consumption, and as proof of principle it has been shown that ALDH2 null variant homozygosity—associated with low alcohol consumption—is indeed related to a lower risk of liver cirrhosis.\(^{100}\) Considerable evidence, including data from randomized controlled trials, suggests that alcohol increases HDL cholesterol levels\(^{101,102}\) (which should protect against CHD) and blood pressure (which should mitigate or reverse the protective effect of alcohol).\(^{103,104}\) In line with this, ALDH2 genotype is strongly associated with HDL cholesterol and hypertension in the expected direction (Table 3). Given the apparent protective effect of alcohol against CHD risk seen in observational studies possession of the ALDH2 allele—associated with lower alcohol consumption—should be associated with a greater risk of myocardial infarction, and this is what was seen in a case-control study.\(^{99}\) Men either homozygous or heterozygous for null ALDH2 were at twice the risk of myocardial infarction. Supporting reasoning that the HDL cholesterol elevating effects of alcohol are what renders it protective against coronary heart disease, statistical adjustment for HDL cholesterol greatly attenuated the association between ALDH2 genotype and CHD.

The ALDH2 example also illustrates some of the complexity in interpreting studies utilizing the Mendelian randomization approach. ALDH2 genotype could be used to study the association between alcohol intake and cancers for which alcohol is a putative cause. In the case of squamous cell carcinoma of the oesophagus the predictions from data suggesting that alcohol increases risk are borne out. In a case-control study, men homozygous for the ALDH2 null variant—and thus likely to drink much less alcohol than their counterparts—had a markedly reduced risk (OR 0.12; which should mitigate or reverse the protective effect of alcohol).\(^{103,104}\) In line with this, ALDH2 genotype is strongly associated with HDL cholesterol and hypertension in the expected direction (Table 3). Given the apparent protective effect of alcohol against CHD risk seen in observational studies possession of the ALDH2 allele—associated with lower alcohol consumption—should be associated with a greater risk of myocardial infarction, and this is what was seen in a case-control study.\(^{99}\) Men either homozygous or heterozygous for null ALDH2 were at twice the risk of myocardial infarction. Supporting reasoning that the HDL cholesterol elevating effects of alcohol are what renders it protective against coronary heart disease, statistical adjustment for HDL cholesterol greatly attenuated the association between ALDH2 genotype and CHD.

Characterizing environmental exposures

**Bile salts and colorectal cancer**

Bile acids are created as part of the metabolism of cholesterol and are grouped into primary bile acids produced by the liver and stored in the gall bladder (these aid digestion of fats and are secreted after a meal) and secondary bile acids produced in the colon by the action of bacteria on primary bile acids. These secondary bile acids are returned to the liver in the entero-hepatic circulation via the portal vein with only a small proportion not being reabsorbed and appearing in the faeces. Active transport at the terminal ileum is the main means by which this reabsorption of bile acids occurs and genetic variations in the ileal sodium-dependent bile acid transporter gene may result in differences in the efficiency of the entero-hepatic reabsorption of bile acids. Epidemiological studies have examined the role of secondary bile acids in the aetiology of colon cancer, as they have the potential to damage cell membranes of the colonic mucosa and might thereby stimulate epithelial proliferation, increasing the risk of adenoma and cancers. A high risk of colonic cancer associated with elevated levels of faecal bile acids has been reported in a number of studies, using both prospective\(^{107-108}\) and case-control methods,\(^{109-111}\) although findings have been equivocal. One of the major problems for studies of this nature is characterizing the exposure variable—levels of secondary bile acids in the colonic lumen—accurately. In addition, many potent confounding factors, such as age, intestinal transit time, stool weight and hepatic function would need to be taken into account. Furthermore, in case-control designs it is highly likely that modifications in diet as a result of colonic disease would make assessments of faecal secondary bile acids unrepresentative of typical levels prior to the onset of disease. In these circumstances, Mendelian randomization may provide a method by which unbiased and unconfounded estimates of the effects on colon cancer risk of lifetime higher levels of colonic bile acids may be made, by comparing the risk of cancer in people with and without variants of the ileal sodium-dependent bile acid transporter gene. Such a study has been conducted examining the effects of polymorphisms of the SLC10A2 gene encoding an ileal sodium-dependent bile acid transporter.\(^{112}\) A case-control design with 458 colorectal adenomas and 504 controls reported an odds ratio of 2.06 (95% CI 1.10, 3.83) for a heterozygous 169 C → T variant compared with homozygous wild type. Interpretation is complicated by the lack of functional significance of the 169 C → T variant, but it is assumed to be in linkage disequilibrium with a functional variant, and functional variants of the SLC10A2 gene have been shown to cause primary bile acid malabsorption.\(^{113}\)

**Intergenerational influences**

**Methyl-tetrahydrofolate reductase (MTHFR) polymorphisms and neural tube defects**

Examining the effects of genotype of parents on the health outcomes of their children introduces the idea of ‘intergenerational’ Mendelian randomization. In these circumstances, exposures of interest relate to aspects of the intrauterine environment that are difficult to measure, but are modified by parental genotype. For example, folate deficiency in pregnancy is now known to be a cause of neural tube defects (NTDs), an effect confirmed by randomized controlled trial evidence.\(^{114,115}\) The MTHFR 677 C → T polymorphism is associated with increased blood levels of homocysteine (equivalent to the situation resulting from lower levels of folate intake) and in a meta-analysis of case-control studies of NTDs, TT mothers had a 2-fold higher risk of having an infant with a neural tube defect than CC mothers.\(^{116}\) The relative risk of a neural tube defect associated with the TT
Mendelian randomization—proving a negative?

Mendelian randomization as a means of testing whether environmental exposures are causal or not has considerable strengths, in that it provides estimates that are largely unconfounded and free from the effects of reverse causality. However, statistical power is low when Mendelian randomization is used in an attempt to refute a causal association. Very large sample sizes may be needed to give sufficiently precise estimates of genotype–phenotype effect to exclude differences of public health and clinical importance.

Consider the example of the association between fibrinogen and CHD, which we have discussed previously. Youngman et al. examined a polymorphism in the promoter region of the β-fibrinogen gene which had a per-allele influence on plasma fibrinogen levels of 0.12 g/l. In their large case-control study, fibrinogen was related to CHD risk, with 0.12 g/l higher fibrinogen being associated with a relative risk of CHD of 1.20 (95% CI 1.13, 1.26). Since 0.12 g/l is the per allele difference in fibrinogen, it would therefore be predicted that there should be a per allele effect on CHD, with a relative risk of approximately 1.20. However, when genotype was related to CHD risk, essentially no relationship was seen, with a per allele relative risk of 1.03 (0.96, 1.10), excluding the estimate obtained by examining the fibrinogen–CHD association. Uncontrolled confounding is a plausible explanation for the difference between the phenotype–CHD and genotype–CHD associations, as fibrinogen levels are higher in smokers, those from deprived backgrounds or with low educational achievement, shorter people (who have higher risk of CHD), and those with raised serum cholesterol levels.

Reverse causality may also play a part here as early, pre-symptomatic atheroma can itself lead to raised fibrinogen levels, generating an automatic—but non-causal—prospective association between fibrinogen and risk of CHD events.

Very large sample sizes are, however, required to provide sufficiently precise estimates of genotype–disease associations to exclude a clinically relevant effect, owing to the small effect sizes expected. The relationships between genotype and disease risk and genotype and fibrinogen levels observed in the study by Youngman et al. imply a risk ratio of 1.3 (95% CI 0.7, 2.2) for a 1 g/l increase in fibrinogen, assuming a linear relationship between fibrinogen and log-risk of CHD. This can be compared with the relative risk of 1.8 (95% CI 1.6, 2.0), for 1 g/l difference in fibrinogen reported in a meta-analysis of fibrinogen-CHD observational epidemiological studies, a test of the difference between these two estimates yields a P value of 0.24. The reason that the genotype–CHD association in the Youngman study is incompatible with the fibrinogen–CHD association is that the latter is of considerably greater magnitude than is seen in the systematic review of this issue. This could reflect greater reverse causation in the Youngman case-control study than in prospective studies (all patients had experienced a heart attack before fibrinogen was measured), or the considerable differential response rates between cases and controls, which could have generated a strongly confounded association. A sample size of around 30 000 cases (and the same number of controls) would be required to have 80% power to exclude a 1.5-relative risk of CHD for the difference in fibrinogen between the top and bottom thirds of the population if there is no true fibrinogen–CHD association.

Limitations of Mendelian Randomization

We dealt extensively with the limitations of Mendelian randomization in our earlier paper (see Table 4), and these have also been discussed elsewhere. Interestingly, several of these limitations were recognized during early discussions of what has come to be known as Mendelian randomization. For example Newcomer et al., who related lactose intolerance to osteoporosis, recognized both confounding by ethnic/racial group (i.e. population stratification) and pleiotropy as potential problems. With respect to Katan’s original example, of apolipoprotein E (apo E) polymorphisms and cancer as a test of the cholesterol—cancer association, some recent (but under-powered) data have suggested that an association may exist.

<table>
<thead>
<tr>
<th>Limitations of Mendelian randomisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Failure to establish reliable genotype—intermediate phenotype or genotype—disease associations</td>
</tr>
<tr>
<td>Confounding of genotype—intermediate phenotype—disease associations</td>
</tr>
<tr>
<td>Pleiotropy and the multi-function of genes</td>
</tr>
<tr>
<td>Canalization and developmental compensation</td>
</tr>
<tr>
<td>Lack of suitable polymorphisms for studying modifiable exposures of interest</td>
</tr>
</tbody>
</table>
Confounding (as in population stratification or linkage disequilibrium) or pleiotrophy as problems for Mendelian randomisation can, at least, be studied through measuring potential confounding factors (as has been done for ALDH2 genotype in Table 3, and for MTHFR genotype elsewhere\textsuperscript{12}). Canalization or developmental compensation is more difficult to study. These processes are considered to reflect developmental buffering against the effect of a polymorphism during fetal development (and perhaps post-natal development). However, different categories of Mendelian randomization are differentially susceptible to this problem. As in the earlier example of ALDH2 polymorphisms and alcohol, if a genotype is associated with a behaviour which is generally only adopted after development has ceased (as is the case with alcohol consumption), canalization is not an issue; in these circumstances genotype–disease associations should reflect associations between the behaviour of interest and health outcomes. Furthermore, intergenerational Mendelian randomization is not susceptible to this problem, since the phenotypic expression (and any canalization) of the parental genotype occurs in the parents, not in the offspring. Adaptation of offspring during development would be the same whether the intrauterine environment was influenced by maternal genotype or by maternal environmental factors. Consequently, the effect of the genotype of the parent on the disease risk of the offspring can be considered free of possible effects of canalization.

### Population attributable risk and non-removable genetic factors

Many critiques of the conceits of genetic epidemiology focus on two features of findings from genetic association studies: that the population attributable risk of the genetic variants is low, and that in any case the influence of genetic factors is not reversible. Illustrating both of these criticisms, Terwilliger and Weiss\textsuperscript{130} suggest as reasons for considering that many of the current claims regarding genetic epidemiology are hype (1) that alleles identified as increasing the risk of common diseases ‘tend to be involved in only a small subset of all cases of such diseases’ and (2) that in any case ‘while the concept of attributable risk is an important one for evaluating the impact of removable environmental factors, for non-removable genetic risk factors, it is a moot point’.

These evaluations of the role of genetic epidemiology are not relevant when considering the potential contributions of Mendelian randomization. This approach is not concerned with the population attributable risk of any particular genetic variant, but the degree to which associations between the genetic variant and disease outcomes can demonstrate the importance of environmentally modifiable factors as causes of disease. Consider, for example, the case of familial hypercholesterolaemia or familial defective apo B. The genetic mutations associated with these conditions will only account for a trivial percentage of cases of CHD within the population—i.e. the population attributable risk will be low. For example, in a Danish population, the frequency of familial defective apo B is 0.08% and despite its 7-fold increased risk of CHD, will only generate a population attributable risk of 0.5%.\textsuperscript{69} However, by identifying blood cholesterol levels as a causal factor for CHD the triangular association between genotype, blood cholesterol and CHD risk identifies an environmentally modifiable factor with a very high population attributable risk.
risk—assuming that 50% of the population have raised blood cholesterol above 6.0 mmol/l and this is associated with a relative risk of 2-fold, a population attributable risk of 33% is obtained. The same logic applies to the other examples discussed above—the attributable risk of the genotype is low, but the population attributable risk of the modifiable environmental factor identified as causal through the genotype–disease associations is large.

The same reasoning applies when considering the suggestion that since genotype cannot be modified, genotype–disease associations are not of public health importance. The point of Mendelian randomization approaches is not to attempt to modify genotype, but to utilize genotype–disease associations to strengthen inferences regarding modifiable environmental risks for disease, and then reduce disease risk in the population through applying this knowledge.

Conclusions

Mendelian randomization approaches have the potential to contribute to an improved understanding of the aetiological importance of environmental factors in common chronic diseases, through reducing the influence on estimated associations of confounding, reverse causation, and various other sources of bias. Categories of inference from Mendelian randomization studies involve propensity to being exposed to a risk factor, proxies for intermediate phenotypes, modifiers of environmental exposures, studying intergenerational exposures, and identifying proxies for intermediate phenotypes, modifiers of environmental studies involve propensity to being exposed to a risk factor, bias. Categories of inference from Mendelian randomization

Acknowledgements

Ian Day, Debbie Lawlor, Sarah Lewis, John Lynch, Neil Pearce, Jonathan Sterne, and Nic Timpson provided helpful comments on earlier drafts of the manuscript.

References

10 Fallon UB. Homocysteine and coronary heart disease—Author’s reply. Heart 2001, published online March 14 (http://heart.bmjournals.com/cgi/eletters/85/2/153).
29 Prediman K, Shah MD, Kaul S, Nilsson J, Carbeck B. Exploiting the vascular protective effects of high-density lipoprotein and its


68. Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolemia. Atherosclerosis 1993;104:1–18.


MENDELIAN RANDOMIZATION: PROSPECTS, POTENTIALS, AND LIMITATIONS


118 Velho G, Hattersley AT, Froguel P. Maternal diabetes alters birth weight in glucokinase-deficient (MODY2) kindred but has no influence on


